Cargando…

1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022

BACKGROUND: Treatment of anal dysplasia has been shown to reduce incidence of squamous cell carcinoma of the anus (SCCA) in PWH, particularly in MSM. Annual anal cytology (PAP) has been offered for SCCA screening since ∼2010 at our urban academic center ambulatory HIV clinics, and those with abnorma...

Descripción completa

Detalles Bibliográficos
Autores principales: Achhra, Amit, Chan, Elizabeth, Applebaum, Serina, Guerrero, Maggie, Hao, Ritche, Pantel, Haddon, Virata, Michael D, Barakat, Lydia A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677807/
http://dx.doi.org/10.1093/ofid/ofad500.1314
_version_ 1785150217312534528
author Achhra, Amit
Chan, Elizabeth
Applebaum, Serina
Guerrero, Maggie
Hao, Ritche
Pantel, Haddon
Virata, Michael D
Barakat, Lydia A
author_facet Achhra, Amit
Chan, Elizabeth
Applebaum, Serina
Guerrero, Maggie
Hao, Ritche
Pantel, Haddon
Virata, Michael D
Barakat, Lydia A
author_sort Achhra, Amit
collection PubMed
description BACKGROUND: Treatment of anal dysplasia has been shown to reduce incidence of squamous cell carcinoma of the anus (SCCA) in PWH, particularly in MSM. Annual anal cytology (PAP) has been offered for SCCA screening since ∼2010 at our urban academic center ambulatory HIV clinics, and those with abnormal PAP (atypical squamous cells of undetermined significance (ASCUS), or Anal Intraepithelial Neoplasia (AIN) 1-3) are referred for high-resolution anoscopy (HRA) and dysplasia treatment. Evaluation of screening cascade can help better understand and improve SCCA screening protocols. METHODS: We performed a retrospective chart review (2018-2022) on MSM PWH, age 35 and older, enrolled at our two HIV clinics who had at least one clinic visit by 12/31/2019. Of total eligible for SCCA screening, we calculated proportion of those engaged (received at least one screening (PAP or HRA)) and retained (received at least one subsequent screening) in care. Characteristics of people who did not engage in screening were evaluated by logistic regression. RESULTS: A total of 432 individuals were eligible for SCCA screening. The median [interquartile range] age was 57 [48-62] years, 97% were on antiretroviral therapy, 28% were Blacks, 62% had history of smoking, and 24% had a prior history of anal dysplasia. A total of 219 (50.7%) engaged in screening, and only 113 (26%) were retained (Figure-1). Seventy-four individuals had at least one abnormal PAP during follow-up, of which 35 (47%) received HRA at least once. In multivariable analysis, older age and history of smoking negatively correlated with engagement while history of anal dysplasia positively correlated with engagement (table-1). Race (Blacks vs other) and type of insurance (public/private) did not correlate with engagement. [Figure: see text] [Figure: see text] CONCLUSION: We noted high rates of loss of engagement and retention in SCCA screening even in PWH highly engaged in HIV care. Older MSM PWH, who are at higher risk of SCCA, were less likely to be engaged in screening. DISCLOSURES: Michael D. Virata, MD, FACP, Gilead Sciences: Advisor/Consultant|Janssen: Advisor/Consultant|ViiV Healthcare: Advisor/Consultant
format Online
Article
Text
id pubmed-10677807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106778072023-11-27 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022 Achhra, Amit Chan, Elizabeth Applebaum, Serina Guerrero, Maggie Hao, Ritche Pantel, Haddon Virata, Michael D Barakat, Lydia A Open Forum Infect Dis Abstract BACKGROUND: Treatment of anal dysplasia has been shown to reduce incidence of squamous cell carcinoma of the anus (SCCA) in PWH, particularly in MSM. Annual anal cytology (PAP) has been offered for SCCA screening since ∼2010 at our urban academic center ambulatory HIV clinics, and those with abnormal PAP (atypical squamous cells of undetermined significance (ASCUS), or Anal Intraepithelial Neoplasia (AIN) 1-3) are referred for high-resolution anoscopy (HRA) and dysplasia treatment. Evaluation of screening cascade can help better understand and improve SCCA screening protocols. METHODS: We performed a retrospective chart review (2018-2022) on MSM PWH, age 35 and older, enrolled at our two HIV clinics who had at least one clinic visit by 12/31/2019. Of total eligible for SCCA screening, we calculated proportion of those engaged (received at least one screening (PAP or HRA)) and retained (received at least one subsequent screening) in care. Characteristics of people who did not engage in screening were evaluated by logistic regression. RESULTS: A total of 432 individuals were eligible for SCCA screening. The median [interquartile range] age was 57 [48-62] years, 97% were on antiretroviral therapy, 28% were Blacks, 62% had history of smoking, and 24% had a prior history of anal dysplasia. A total of 219 (50.7%) engaged in screening, and only 113 (26%) were retained (Figure-1). Seventy-four individuals had at least one abnormal PAP during follow-up, of which 35 (47%) received HRA at least once. In multivariable analysis, older age and history of smoking negatively correlated with engagement while history of anal dysplasia positively correlated with engagement (table-1). Race (Blacks vs other) and type of insurance (public/private) did not correlate with engagement. [Figure: see text] [Figure: see text] CONCLUSION: We noted high rates of loss of engagement and retention in SCCA screening even in PWH highly engaged in HIV care. Older MSM PWH, who are at higher risk of SCCA, were less likely to be engaged in screening. DISCLOSURES: Michael D. Virata, MD, FACP, Gilead Sciences: Advisor/Consultant|Janssen: Advisor/Consultant|ViiV Healthcare: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10677807/ http://dx.doi.org/10.1093/ofid/ofad500.1314 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Achhra, Amit
Chan, Elizabeth
Applebaum, Serina
Guerrero, Maggie
Hao, Ritche
Pantel, Haddon
Virata, Michael D
Barakat, Lydia A
1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title_full 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title_fullStr 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title_full_unstemmed 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title_short 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
title_sort 1478. evaluation of anal cancer screening program in men who have sex with men (msm) persons with hiv (pwh) at two academic center hiv clinics 2018-2022
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677807/
http://dx.doi.org/10.1093/ofid/ofad500.1314
work_keys_str_mv AT achhraamit 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT chanelizabeth 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT applebaumserina 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT guerreromaggie 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT haoritche 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT pantelhaddon 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT viratamichaeld 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022
AT barakatlydiaa 1478evaluationofanalcancerscreeningprograminmenwhohavesexwithmenmsmpersonswithhivpwhattwoacademiccenterhivclinics20182022